HAIFA, Israel, September 26 /PRNewswire/ -- InSightec's ExAblate(R) 2000, the first U.S. Food and Drug Administration (FDA) approved Magnetic Resonance-guided Focused Ultrasound (MRgFUS) technology for the non-invasive treatment of uterine fibroids has once again been recognized for technology achievement, the company said today. Frost & Sullivan, the international growth consultant, has awarded InSightec its 2005 Technical Innovation Award in the field of non-invasive medical devices for outstanding industry achievement. Frost & Sullivan's gives the Technology Innovation award to a company that has carried out new research that has resulted in innovation expected to bring significant contributions to its industry in terms of adoption, change, and competitive posture. This award recognizes the quality and depth of a company's research and development program as well as the vision a company had and the risks it took to undertake such an endeavor. "This is the fourth in a line of prestigious awards InSightec has received for the ExAblate 2000 technology," Dr. Jacob Vortman, president and CEO, InSightec said. "We are pleased by this, but more importantly, we are rewarded that so many women have already benefited from this patient-friendly solution for treating uterine fibroids and are investing in research on future applications that will enable other patients suffering from breast cancer, liver cancer, bone tumors, prostate cancer and brain tumors to be treated non-invasively for their tumors." In November 2004, The Wall Street Journal awarded the Company a Bronze Medal and Second Place in the Medical Category as part of its annual Technology Innovation Awards. Out of 585 applicants, the Journal picked the novel ideas that best addressed big challenges and had a wide-reaching impact. Rigorous data had to support the winners' real-world performance. Also in 2004, the European Information Society Technology awarded InSightec the IST Grand Prize, the most distinguished European Prize for innovative products and services in the field of information society technology. The award is given based on technical excellence, innovative content, potential market value, and the capacity to generate new jobs. Most recently, the ExAblate 2000 was also recognized by Advanced Imaging in its 2005 Solutions of the Year issue. The ExAblate 2000 uses magnetic resonance imaging (MRI) in conjunction with highly-focused ultrasound to thermally ablate (destroy) tumors in the body. The unique MR thermometry feedback, provided by the system, allows the physician to monitor and control the treatment to ensure that the targeted tumor is fully treated and the healthy tissue is avoided. The ExAblate 2000 is compatible only with GE Healthcare's SIGNA Magnetic Resonance systems. The system is currently in use at centers around the world for the treatment of uterine fibroids and clinical research trials are underway for potential applications in the treatment of both benign and cancerous tumors. For more information about the ExAblate(R) 2000 or InSightec, please visit www.insightec.com. About InSightec InSightec Image Guided Treatment Ltd. is a privately held company owned by Elbit Medical Imaging (EMI), General Electric, private investors and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 100 employees and has invested more than $80 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/ Contact Information InSightec www.insightec.com Tel: +972-4-813-1329 Email: firstname.lastname@example.org For media inquiries, contact: Fern Lazar Lazar Partners, Ltd. Tel: +1-(212)-867-1762 Email: email@example.com For more information, please visit http://www.uterine-fibroids.org
SOURCE Insightec Ltd.